Treatment Beyond Progression with Atezolizumab in Extensive-Stage SCLC: Exploratory Analysis from the IMfirst Study

Previous reports from IMfirst (EudraCT: 2019-002784-10), a phase IIIB, single-arm study of carboplatin/cisplatin plus etoposide with atezolizumab (ATZ) in patients with untreated extensive-stage small cell lung cancer (ES-SCLC), confirmed the safety and efficacy profile of ATZ plus chemotherapy in a real-world clinical setting in Spain. The current standard of care for this indication is platinum-etoposide + anti-PD-L1 inhibitors, but progressive disease (PD) in ES-SCLC requires subsequent lines of treatment, with limited efficacy and high toxicity.